Valuation dashboard for Johnson & Johnson (JNJ) with P/E 41.42, P/B 8.37, EV/EBITDA 22.67 and dividend yield 1.89%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Analysis Summary
Johnson & Johnson reported revenue of $94.19B in the most recent fiscal year, growing at a 5-year CAGR of 2.7%. Net income reached $26.80B, with a 12.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 68.8%, operating margin 25.7%, net margin 16.2%.
At $273.20 (closing price, October 30, 2026), JNJ trades at a P/E of 41.42 and an ROE of 19.55%. Market capitalisation stands at $657.7B, placing it among large-cap names.
Balance sheet quality for JNJ: current ratio of 1.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 41.42 |
| Price / Book | 8.37 |
| EV / EBITDA | 22.67 |
| Dividend Yield | 1.89% |
Valuation Models
| DCF Fair Value | $289.92 |
| vs Current Price | +6.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $657.7B | 41.42 | 8.37 | 19.6% |
| MRK | Merck & Co., Inc. | $368.9B | 119.62 | 8.84 | 5.1% |
| AMGN | Amgen Inc. | $251.9B | 28.96 | 21.53 | 89.3% |
| GILD | Gilead Sciences, Inc. | $211.6B | 16.26 | -21.7% | |
| SNY | Sanofi | $106.9B | 23.29 | 1.32 | 5.5% |
| ABBV | AbbVie Inc. | $521.1B | 83.08 | -136.5% | |
| AZN | AstraZeneca PLC | $289.5B | 28.03 | 5.74 | 21.7% |
| NVS | Novartis AG | $303.7B | 30.69 | 8.22 | 24.2% |
Price
| Price | $273.20 (closing price, October 30, 2026) |
| Market Cap | $657.7B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 19.55% |
| Return on Invested Capital | 15.36% |
| Return on Assets | 8.15% |
| Gross Margin | 68.81% |
| Operating Margin | 25.70% |
| Net Margin | 16.20% |
Related companies: MRK · AMGN · GILD · SNY · ABBV · AZN · NVS · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of JNJ: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks